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Purpose
Recurrence and chemoresistance (CR) are the leading causes of death in patients with high-
grade serous carcinoma (HGSC) of the ovary. The aim of this study was to identify genetic
changes associated with CR mechanisms using a patient-derived xenograft (PDX) mouse
model and genetic sequencing. 
Materials and Methods
To generate a CR HGSC PDX tumor, mice bearing subcutaneously implanted HGSC PDX 
tumors were treated with paclitaxel and carboplatin. We compared gene expression and
mutations between chemosensitive (CS) and CR PDX tumors with whole exome and RNA
sequencing and selected candidate genes. Correlations between candidate gene expression
and clinicopathological variables were explored using the Cancer Genome Atlas (TCGA) data-
base and the Human Protein Atlas (THPA). 
Results
Three CR and four CS HGSC PDX tumor models were successfully established. RNA 
sequencing analysis of the PDX tumors revealed that 146 genes were significantly up-reg-
ulated and 54 genes down-regulated in the CR group compared with the CS group. Whole
exome sequencing analysis showed 39 mutation sites were identified which only occurred
in CR group. Differential expression of SAP25, HLA-DPA1, AKT3, and PIK3R5 genes and
mutation of TMEM205 and POLR2A may have important functions in the progression of
ovarian cancer chemoresistance. According to TCGA data analysis, patients with high HLA-
DPA1 expression were more resistant to initial chemotherapy (p=0.030; odds ratio, 1.845).     
Conclusion
We successfully established CR ovarian cancer PDX mouse models. PDX-based genetic pro-
filing study could be used to select some candidate genes that could be targeted to over-
come chemoresistance of ovarian cancer.
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Introduction
Targeting chemoresistant (CR) or recurrent cancer has 
become an important strategy for treatment of high-grade
serous carcinoma (HGSC) of the ovary. This is due to the fact
that up to 80% of patients with HGSC will eventually expe-
rience recurrence or disease progression due to resistance to
chemotherapy, even if they were highly responsive to first-
line platinum-based chemotherapy and achieved pathologic
complete response [1,2]. However, standard second-line
chemotherapy for resistant or recurrent HGSC is still contro-
versial. Heterogeneity of genetic mutation is one of major
reasons for the chemoresistance of ovarian cancer [3,4]. 
Recently, personalized precision medicine for various can-
cers has been widely studied as a potential means of over-
coming heterogeneity of cancer. Although some genetic
aberrations in CR ovarian cancers have been reported, gene-
tic profiling methods such as the Cancer Genome Atlas
(TCGA)’s molecular landscape of cancer have shown that 
epithelial ovarian cancer is deficient in recurrent actionable
mutations [5]. Thus, the development of individualized ther-
apy remains an unmet medical need for patients with resist-
ant HGSC [6]. 
Patient-derived xenograft (PDX) models, which directly
implant fresh human tissue into immune-compromised
mice, have increasingly been used in preclinical in vivo study.
Many researchers have identified not only that PDX models
can recapitulate the genetic, heterogeneous characteristics of
the original cancer [7,8] but also that their therapeutic 
responses are concordant with the source patient experience.
PDX models have therefore been used broadly in oncology
research as reliable patient “avatars.” In this study, in order
to reflect the characteristics of donor tumors more accurately,
we generated CR HGSC PDX models by intraperitoneal 
injection of first-line chemotherapeutic agents of ovarian can-
cer and selected CR and chemosensitive (CS) cases.
With regard to unraveling the mechanisms underlying
chemoresistance, other researchers have demonstrated the
genetic alterations that regulate the critical steps of the che-
moresistance process. Previous studies have proposed a few
genes or pathways associated with chemoresistance using
microarrays or copy number variation analysis [9]. However,
these genetic changes had been incompletely characterized
in terms of first-line (carboplatin, paclitaxel) chemotherapy
response, and few studies have used genetic sequencing in
order to identify the exact factors correlated with chemore-
sistance in PDXs. In this study, we performed whole exome
sequencing PDX tissues to detect genetic mutation, and RNA
sequencing to compare the genetic profiles of CS and CR
HGSC PDX tissues. Differently expressed genes (DEGs) were
further identified to select candidate genes highly suspected
to be associated with chemoresistance and therefore to offer
the potential for personalized, targeted treatment options.
Materials and Methods
1. Patients and tissue samples
We enrolled seven patients who had HGSC of the ovary in
International Federation of Gynecology and Obstetrics stage
III to IV of the disease. Tumor specimens were collected dur-
ing primary debulking or diagnostic surgery between 
August 2014 and October 2016. Data on the patients’ clinical
characteristics were obtained from chart review. Recurrence
was defined as a positive radiological examination with a
serum carbohydrate antigen 125 assay of more than 35 U/mL
after the completion of first line platinum-based chemother-
apy.
2. Establishment of CR PDX model
All of the female BALB/c nude mice used in this study
were purchased from Orient Bio (Seongnam, Korea). All 
animal experiments were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the Yonsei Uni-
versity College of Medicine. Fresh tumor tissues from con-
senting patients with primary HGSC of the ovary were col-
lected at the time of debulking or diagnostic surgery at Sev-
erance Hospital (passage zero). These tissues (about 5!5!3
mm3) were transplanted subcutaneously into 6-8-week-old
nude mice within one hour of removal of tissues. Tumor
growth was monitored 2-3 times per week, and tumor vol-
ume was calculated by the formula 1/2(width2!length). To
establish CR HGSC PDX model, 12 mice were engrafted with
PDX tumor of passage 2 or 3 in each PDX model. Paclitaxel
and carboplatin combination chemotherapy was initiated
when tumor volumes reached around 700 mm3. Engrafted
mice were randomly divided into two groups: (1) normal
saline (control group); (2) paclitaxel 15 mg/kg and carbo-
platin 50 mg/kg, every 7 days, four cycles, intraperitoneal
injection (T+C group). The PDX models that showed tumor
regression by more than 70% in every mice was assigned to
a CS group, while consistent growth of tumor in every mice
was assigned to a CR group.
3. Nucleic acid isolation
About 3!3!3-mm3 (0.1 g) tissues were used to extract 
nucleic acid. Extracted DNA was quantified by Quant-iT BR
assay kit (Invitrogen, Carlsbad, CA). Total RNAs from inde-
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pendent tissues were isolated using RNeasy Mini Kit (Qia-
gen, Hilden, Germany). The 10 µL (100 ng/µL) DNA and the
10 µL (250 ng/µL) RNA of each samples were sent to proceed
genetic analysis. The quality of RNAs was checked via
28S/18S ratio and RNA integrity number (RIN) value using
the Agilent Bioanalyzer 2100 system (Agilent Technologies,
Santa Clara, CA). Total RNAs with RIN values greater than
7.0 were taken for subsequent downstream analysis.
4. Whole exome sequencing and analysis
Whole exome-sequencing (WES) capturing sequencing
was performed using a 51 Mb SureSelect V5 Kit (Agilent
Technologies) according to the manufacturer’s instructions.
DNA libraries were constructed according to the protocol
provided by the manufacturer, and WES was performed
using an Illumina HiSeq2500 platform (Illumina, San Diego,
CA) to generate 101bp paired-end reads. To separate human
and mouse WES reads, we used BBsplit together with BBmap
package (https://sourceforge.net/projects/bbmap/). We
used Cutadapt and sickle to remove adapter sequences and
low-quality sequence reads. A Burrows-Wheeler aligner [10]
was used to align the sequencing reads onto the human ref-
erence genome (hg19). We used a Genome Analysis ToolKit
[11] for local realignment, score recalibration and filtering 
sequence data. Somatic genomic variants were identified
using MuTect to call somatic point mutations. SnpEff was
used to select somatic variants located in coding sequences
and predict their functional consequences, such as silent or
non-silent variants. The details of WES and alignments were
summarized in S1-S5 Tables.
5. RNA sequencing and analysis
mRNA sequencing was performed using a TruSeq RNA
Library Prep Kit (Illumina). Whole-transcriptome sequencing
was performed using an Illumina HiSeq2500 platform. We
used in-house script to trim low quality reads, and we ana-
lyzed filtered sequence data using STAR [12] for alignment,
Cufflinks v2.2.1 [13] for assembly, and a known set of refer-
ence transcripts from Ensembl v72 for expression estimation.
To count the DEGs, we used Cuffdiff of Cufflinks package
v2.2.1. For functional enrichment analysis, we performed
Gene Ontology (http://www.geneontology.org/) and Kyoto
Encyclopedia of Genes and Genome (KEGG) pathway analy-
sis (http://www.kegg.jp/). 
6. Utilization of TCGA and THPA data
We searched the TCGA database (https://tcga-data.nci.
nih.gov/tcga/tcgaDownload.jsp) and collected ovarian can-
cer patient genetic profiling and clinical data. Kaplan-Meier
analysis of the correlation between RNA gene expression lev-
els and overall survival was available in THPA (https://
www.proteinatlas.org/). There are no restrictions on the
publication and use of these data.
7. Histopathology and immunohistochemistry
Hematoxylin and eosin (H&E) staining of formalin-fixed
tumor tissues from patient and PDX tissues were performed.
Immunohistochemistry (IHC) staining was performed on 
4-µm sections prepared from harvested PDX tumor tissue.
Slides were incubated with antibodies against AKT3 (1:500,
ab152157, Abcam, Cambridge, UK), PIK3R5 (1:150, NBP2-
46413, Novus, Littleton, CO), HLA-DPA1 (1:500, NBP2-
16851, Novus), and SAP25 (1:50, NBP2-32365, Novus), after
which slides were treated with 3,3'-diaminobenzidine (Dako,
Glustrup, Denmark). Staining intensity of the cells was
scored at four fields from each sample at 400! magnification
by three examiners. It was scored as 0 (negative staining), 1
(week staining), 2 (intermediate staining), and 3 (strong
staining). 
8. Quantitative real-time polymerase chain reaction
Total RNAs was extracted using a TruSeq RNA Library
Prep Kit (Illumina). RNA was converted to cDNA using a 
reverse transcription reagent kit (Bioline, London, UK) and
amplified using SensiFAST SYBR Hi ROX Mix (Bioline). ABI
StepOnePlus Real Time PCR System (Applied Biosystems,
Foster City, CA) was used to conduct quantitative real-time
polymerase chain reaction (qRT-PCR). 18S was the internal
standard and relative gene expression was calculated using
the 2-!!CT method. CS1 was served as control values. Pri-
mers used for each gene were shown in S6 Table. 
9. Statistical analysis
Receiver operating characteristic curves were used to iden-
tify high and low RNA expression of genes. A chi-square test
was used to assess the relationship between RNA expression
and patient response to initial chemotherapy. Statistical cal-
culation was performed using SPSS ver. 23.0 (IBM Corp., 
Armonk, NY). A p-value of < 0.05 was considered statisti-
cally significant. Hierarchical clustering of DEGs between CS
and CR PDX groups was performed using R studio v 0.99.903
(RStudio Inc., Boston, MA).
10. Ethical statement
This study was approved by the Yonsei University Sever-
ance Hospital Institutional Review Board (IRB) in accordance
with the Helsinki Declaration (IRB number: 4-2013-0526). All
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participants provided written informed consent before 
enrolling in this study.
Results
1. Establishment of CR PDX model from serous ovarian
cancer 
We selected seven HGSC PDXs from our previously estab-
lished ovarian PDX tumor bank. Four cases were assigned to
Cancer Res Treat. 2019;51(3):1117-1127
Fig. 1.  Different chemoresponses in six ovarian patient-derived xenograft models. Three cases (CS1, CS2, and CS3) showed
regression of tumor, three cases (CR1, CR2, and CR3) showed consistent growth of tumor. CS, chemosensitive; CR, chemore-
sistant; T, paclitaxel; C, carboplatin; ▲, chemotherapy injection.
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a CS group and three cases were assigned to a CR group 
according to the chemoresponse of PDX model (Fig. 1). These
seven PDX models and their corresponding patients had
similar responses to chemotherapy (S7 Table). We selected
three cases of CS (CS1, CS2, and CS3) group and three cases
of CR (CR1, CR2, and CR3) group to perform genetic analy-
sis. All the CR3 tumors were harvested 2 weeks after chemo
agent injection due to the speed at which the tumors were
growing.
2. DEG data and target genes
The RNA sequencing was successful in five PDX models
and unsuccessful in one model. Sequencing of the CR3 tumor
failed because the tissue contained too many mouse genes
with a low coverage of human genes. We set cut-off criteria
for the purpose of screening out the genes specific for CR 
patients. As for the up-regulated genes, only those genes
with expression levels > 1 fragments per kilobase million
(FPKM) and 2.5-fold more expression than opposite groups
were selected in this study. Total 200 genes were determined
to be differentially expressed between the CS and CR groups
of the PDX model, including 146 up-regulated genes and 54
down-regulated genes in the CR group. Of these genes 
(excepting those genes that were uncharacterized), SAP25
differed most in its expression (S8 Table). Hierarchical clus-
tering of the 200 differentially expressed genes is presented
in Fig. 2A. The results of the KEGG pathways analysis
showed that complement and coagulation cascades, cell 
adhesion molecules, and extracellular matrix–receptor inter-
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Fig. 2.  Genetic expression of frequently expressed genes and validation of candidate genes in patient-derived xenograft
(PDX). (A) Unsupervised hierarchical clustering analysis using 200 selected genes differentially expressed between chemosen-
sitive (CS) and chemoresistant (CR) groups. FPKM, fragments per kilobase million. (Continued to the next page)
A
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action (KEGG p=0.001, p=0.001, and p=0.003, respectively)
signal pathways were the most significantly impacted can-
cer-related pathways in CR groups compared to CS groups.
Among the genes involved in these pathways, we found that
cell adhesion pathway related HLA-DPA1 gene was the most
up-regulated gene (> 88 fold FPKM than CS groups) in the
CR group (S8 Table). 
3. Whole exome sequencing data analysis
An average of 30,460 and 27,944 somatic mutations were
observed in the CS and CR group, respectively, and the ave-
rage respective sequencing depths were 110 and 115. A to T
transversions was the most frequent somatic mutations in
each PDX tissues (A to T ratio, 38%-40%). Of the mutations
occurred only in CR groups, the A to T ratio increased to 65%
(Fig. 3A). A total of 39 mutation sites were identified which
only occurred in chemoresistant group (S9 Table). Interest-
Cancer Res Treat. 2019;51(3):1117-1127
Fig. 2.  (Continued from the previous page) (B) Immunohistochemical (IHC) staining of AKT3, PIK3R5, HLA-DPA1, and SAP25
in PDX (!400). Expression levels of AKT3, PIK3R5, HLA-DPA1, and SAP25 were much lower in CS cases than in CR (BC, 
before chemotherapy; PC, post chemotherapy). (C) IHC staining intensity of AKT3, PIK3R5, HLA-DPA1, and SAP25 in CS
and CR group. The protein expression levels of four genes were significantly higher in each CR group in comparison with
CS. (D) Quantitative real-time polymerase chain reaction analysis of AKT3, PIK3R5, HLA-DPA1, and SAP25 expression in
PDX. The mRNA expression level of four genes were significantly increased in each CR group in comparison with CS group.
**p < 0.01, ***p < 0.001.
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Gene name REF ALT
Gene expression (FPKM)
CR1 CR2 CS1 CS2 CS3 CR/CS ratio
CCDC159 G GA 62.45 108.96 25.26 25.89 58.52 2.34
INTS4 A AT 18.42 21.28 25.9 24.71 41.81 0.64
POLR2A T TAGA 41.56 17.17 16.16 33.53 29.25 1.15
SPG7 T TATCTC 46.1 68.42 62.55 36.59 41.62 1.22
TMEM205 G GA 251.23 204.28 107.63 120.47 172.26 1.71
Table 1. Gene expression level of five insertion variants 
REF, reference allele; ALT, alternative allele; FPKM, fragments per kilobase million; CR, chemoresistant; CS, chemosensi-
tive.
Fig. 3.  Somatic mutation in five patient-derived xenograft (PDX) models. (A) The proportion of mutational type in five PDX
tissues. (B) Number of mutated genes by pathway. The phosphoinositide 3-kinase (PI3K)-AKT and mitogen-activated protein
kinase (MAPK) signaling pathways exhibited relatively more mutated genes than other pathways in all PDXs. CR, chemore-
sistant; CS, chemosensitive.
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ingly, of these mutation genes, the expression level of four
insertion genes (CCDC159, POLR2A, SPG7, and TMEM205)
increased in CR groups compared with CS groups (Table 1).
We could hypothesis that these insertion mutation genes
may lead to chemoresistance of ovarian cancer. The phos-
phoinositide 3-kinase (PI3K)–Akt signaling pathway and the
mitogen-activated protein kinase signaling pathway had the
greatest number of mutated genes in all PDX models (164-
182 and 134-152 mutated genes, respectively) (Fig. 3B). 
Although there was no difference in the number of mutated
genes between the CS and CR group, the results above sug-
gest that the mutated genes in these pathways might have
stronger associations with ovarian cancer. Furthermore, we
found that the AKT3 and PIK3R5 genes involved in the PI3K-
Akt signaling pathway were on the list of 200 selected DEGs.
4. Clinical association of selected genes
Based on WES data and data concerning the top differen-
tially expressed genes, we identified the SAP25, HLA-DPA1,
AKT3, and PIK3R5 genes as candidate genes possibly invol-
ved in the mechanism underlying chemoresistance. We ana-
lyzed the RNA expression of the four candidate genes in 236
ovarian cancer patients from TCGA database and explored
their correlations with initial chemotherapy response. Of the
236 ovarian cancer patients, 161 had shown complete remis-
sion during chemotherapy, while 75 showed partial remis-
sion, progression, or stable disease. According to the expre-
ssion level of HLA-DPA1, rather than SAP25, AKT3, or PIK3-
R5, there was a significant difference in patients’ initial
chemoresponse (p=0.030; odds ratio, 1.845) (Table 2). Patients
with high expression of HLA-DPA1 were more resistant to
initial chemotherapy. According to THPA data, patients with
low expression of SAP25 had slightly better survival than
those with high expression of the gene (p=0.050) (S10 Fig.).  
5. Validation of selected genes by IHC and qRT-PCR
Following H&E staining of patient and corresponding
PDX tissues, we were able to determine that that patient can-
cer cell morphology was retained in most of the PDX models
(S11 Fig.). We observed many stromal or fibrous cells in both
the CR2 and CR3 PDX slides, and this was even more obvi-
ous after chemotherapy. To examine the expression of 
selected genes in PDX tissues, IHC and qRT-PCR were done
on CS and CR PDX tissues. As determined by RNA-sequenc-
ing, IHC staining showed higher protein expression levels of
all four genes in the CR group compared to the CS group
(Fig. 2B and C). qRT-PCR analysis also showed that AKT3,
PIK3R5, HLA-DPA1, and SAP25 overexpressed in CR groups
compared with that in CS groups (Fig. 2D).  
Discussion
Platinum-based chemotherapy is still a standard treatment
despite the well-known fact that 80% of primary ovarian can-
cer cases will exhibit chemoresistance and recurrence [2].
Specialized therapy targeting the mechanisms underlying
chemoresistance during the early phase of treatment is 
urgently needed for ovarian cancer patients. Although the
TCGA database provided useful genetic data for researchers,
ovarian cancer is still deficient in recurrent actionable muta-
tions. Besides, ovarian cancer always requires time to recur,
Cancer Res Treat. 2019;51(3):1117-1127
Table 2.  Correlation of selected gene expression and initial chemotherapy response in TCGA data
Expression PR, PD, SD Complete remission p-value ORa)
SAP25
High 31 55 0.286 1.358 (0.773-2.385)
Low 44 106
HLA-DPA1
High 44 70 0.030 1.845 (1.059-3.215)
Low 31 91
AKT3
High 38 75 0.559 1.178 (0.681-2.038)
Low 37 86
PIK3R5
High 35 82 0.542 0.843 (0.487-1.459)
Low 40 79
TCGA, the Cancer Genome Atlas; PR, partial remission; PD, progression of disease; SD, stable disease; OR, odd ratio. a)Odds
ratio (OR) > 1 indicated more resistant to initial chemotherapy than reference groups.
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and physicians have not been able to accurately predict
chemoresponse accurately during the early phases of treat-
ment, much less get the patient’s resistant sample. In our
study, we used PDX to set up a CR model in a short period
of time and then executed whole exome sequencing and
RNA sequencing DEG analysis with CS and CR cancer tis-
sues harvested from PDX mice in order to identify potential
actionable molecular targets related to chemoresistance. The
overall workflow of selecting candidate genes is summarized
in S12 Fig.
Nevertheless, single gene alterations alone were not able
to generate chemoresistance. Alteration of metabolic factors
and pathways act in concert to change cancer cell character-
istics [14]. In the DEGs of the cell adhesion pathway, major
histocompatibility complex (MHC) class II molecule genes
(HLA-DOA, HLA-DPA1, and HLA-DRA) were in the list of
200 genes that they significantly up-regulated in CR groups.
This suggests that these MHC class II molecules have an 
important effect on the mechanism underlying cancer che-
moresistance. This result was in agreement with other stud-
ies, which found that the MHC complex played a main role
in ovarian immunology and that both HLA class I and II mol-
ecules contributed to resistance to treatment [15,16]. This 
result was further validated by the TCGA database, which
predicted that patients with high expression of HLA-DPA1
would be more CR to initial chemotherapy. Thus, HLA-DPA1
expression could serve as a predictor of initial chemotherapy
results and might also be a gene that could be targeted in the
treatment of CR cancers.
Additionally, SAP25was the most differentially expressed
between the CS and CR group. This gene was known as a
novel component of the mSin3A complex. mSin3A is known
to be involved in cell fate, and its core binding proteins (such
as SAP25) may also have different effects on cell behavior
[17]. Hence, we could hypothesize that SAP25 might have
played a role in the mechanisms underlying chemoresis-
tance, but further research would be needed to prove this. 
PI3K/AKT signaling pathway has been widely investi-
gated as a treatment target due to the role it plays in regulat-
ing cell growth, cell survival, angiogenesis, tumorigenesis,
and drug resistance [18]. Dysregulation of this pathway and
high frequency aberrations had been observed in several
human cancers, including ovarian cancer [19-21]. This was
consistent with our WES results. As for PI3K, much preclin-
ical research has supported the use of PI3K inhibitors as 
anticancer agents and many clinical trials of PI3K inhibitors
are being performed by pharmaceutical companies or insti-
tutions to further evaluate their effect on CR cancers [22].
AKT3was significantly up-regulated in our CR group, which
suggested the possibility of AKT3 as a target for therapy.
Liby et al. [23] demonstrated that blocking AKT3 alone could
eliminate vascular endothelial growth factor secretion in
ovarian cancer cells and reduce tumor vascularization in
PDX models. AKT’s anticancer effect has also been validated
in Phase I clinical trials, and other clinical trials investigating
small molecule inhibitors of AKT are still ongoing [24].
Determining the WES in ovarian cancer PDX model iden-
tified four insertion genes (CCDC159, POLR2A, SPG7, and
TMEM205) mutated only in CR groups. Of these genes, TMEM-
205was known as associated with cisplatin resistance in lung
cancer. The effect of overexpression of TMEM205 in lung
cancer on cisplatin resistance has been confirmed and is sug-
gested as a biomarker and target in clinical chemotherapy
[25]. Besides, Wang et al. [26] showed that polymorphism of
TMEM205was significantly associated with platinum-based
chemotherapy response in lung cancer. They further hypoth-
esize that the location of gene or the variant can regulate the
expression of gene. It is consistent with our result that the 
expression of TMEM205 in TMEM205 insertion variant CR
groups was higher (1.7 fold) than that in non-variant CS
groups. However, the potential mechanisms of gene expres-
sion regulated by mutated genes remains to be further stud-
ied [26]. POLR2A encodes largest RNA polymerase II com-
plex and is responsible for cell proliferation including ovar-
ian and colon cancer. Liu et al. [27] demonstrated that sup-
pression of POLR2A could selectively inhibit the tumorigenic
potential of colorectal cancer cells [28]. Furthermore, poly-
morphisms of POLR2Awere associated with worse survival
outcomes in non-small cell lung cancer [29]. Although little
research has been done on the effect of POLR2A insertion
variant on tumor chemoresistance, these studies paved the
way for a better understanding of the effect of TMEM205 and
POLR2Amutation on the gene expression which is correlated
with chemoresistance in the cancer. 
In summary, we set up a CR PDX model by replicating the
exact treatment scheme used on its donor patients. For the
purpose of identifying genes that play vital roles in the 
development of chemoresistance, we integrated WES and
DEG analysis to increase accuracy. The result showed that
differential expression of SAP25, HLA-DPA1, AKT3, and
PIK3R5 genes and mutation of TMEM205 and POLR2Amay
have important functions in the progression of ovarian can-
cer chemoresistance. This preliminary PDX-based genetic
profiling study could serve as a platform for further research
on chemoresistance in ovarian cancer. However, further
studies are needed to validate the effectiveness of these 
selected genes’ inhibitors in ovarian cancer PDX models or
in corresponding ovarian cancer patients.
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